Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for PCRX-201 (enekinragene inzadenovec) in Knee osteoarthritis. The expected timing is based on the latest available company guidance and may change.
ASCEND trial. 3/13/24- RMAT designation. 4/3/25- First patient dosed. 10/28/25- Presented at ACR'25. 11/5/25– Concluded patient enrollment in Part A. Topline data by YE 2026. 11/06/25:- Company reiterates ASCEND Part A enrollment completion and expects topline data near YE 2026. 02/26/26:- PR No update. 04/30/26:- Company reiterates key 2026 ASCEND Part A Phase 2 knee OA readout, entering data-rich period. 08/04/26:- ASCEND Part B enrollment underway; Part A topline data expected by YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.